Literature DB >> 15585088

Potential drug resistance polymorphisms in the integrase gene of HIV type 1 subtype A.

Belinda L Herring1, Anthony L Cunningham, Dominic E Dwyer.   

Abstract

Variation in HIV-1 genes within and between subtypes has been best defined in the env gene, however, other more conserved genes vary between subtypes. Integrase (IN) and other regions of the pol gene are highly conserved due to their integral role in HIV replication and therefore are targets for antiviral drugs. In this study 3 individuals, infected heterosexually with HIV-1 subtype A, were examined for IN polymorphisms. Two patients' sequences clustered phylogenetically with other subtype A sequences and one patient's sequence was most similar to the circulating recombinant form CRF_02. No polymorphisms were observed in either of the motifs containing residues critical residues for IN activity. Polymorphisms were observed in a residue associated with resistance to anti-integrase drugs. In addition, a number of unique polymorphisms were observed in one individual (WM1666). IN can vary significantly within a subtype as well as between subtypes, and mutations associated with resistance to anti-integrase compounds can be present in drug naive individuals.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15585088     DOI: 10.1089/aid.2004.20.1010

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  1 in total

1.  Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.

Authors:  Isabelle Malet; Olivier Delelis; Marc-Antoine Valantin; Brigitte Montes; Cathia Soulie; Marc Wirden; Luba Tchertanov; Gilles Peytavin; Jacques Reynes; Jean-François Mouscadet; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.